Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
February 18, 2019

Bavencio plus Inlyta improves median PFS in renal carcinoma study

Pfizer and Merck have announced that Bavencio (avelumab) plus Inlyta (axitinib) has improved median progression-free survival (PFS) in renal carcinoma study.

Image: Pfizer headquarters. Photo: courtesy of Coolcaser.